| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.80 [0.62, 1.03] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | crucial | - |
| PFS (extension) | 0.69 [0.58, 0.83] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.69 [0.56, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 2.95 [2.23, 3.90] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (grade 3-4) | 0.98 [0.73, 1.32] | | < 1 | | 0% | 1 study (1/-) | 54.3 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 3.05 [0.32, 29.42] | | < 1 | | 0% | 1 study (1/-) | 16.9 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.53 [0.34, 0.83] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.78 [0.40, 1.53] | | < 1 | | 0% | 1 study (1/-) | 76.2 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 1.06 [0.81, 1.38] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Anaemia TRAE (grade 3-4) | 0.04 [0.01, 0.33] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 2.03 [0.07, 60.53] | | < 1 | | 0% | 1 study (1/-) | 34.4 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.63 [0.20, 1.93] | | < 1 | | 0% | 1 study (1/-) | 79.1 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 2.03 [0.07, 60.53] | | < 1 | | 0% | 1 study (1/-) | 34.4 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.78 [0.52, 6.13] | | < 1 | | 0% | 1 study (1/-) | 18.0 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 2.08 [0.99, 4.34] | | < 1 | | 0% | 1 study (1/-) | 2.6 % | NA | not evaluable | | non important | - |
| Dysgeusia TRAE (grade 3-4) | 1.01 [0.02, 51.10] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Dyspepsia TRAE (grade 3-4) | 1.01 [0.02, 51.10] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Dysphonia TRAE (grade 3-4) | 4.06 [0.18, 90.30] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 6.14 [0.74, 51.22] | | < 1 | | 0% | 1 study (1/-) | 4.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.82 [0.39, 1.72] | | < 1 | | 0% | 1 study (1/-) | 70.3 % | NA | not evaluable | | non important | - |
| Hypertension TRAE (grade 3-4) | 1.79 [1.28, 2.52] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.01 [0.06, 16.22] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 2.05 [0.76, 5.52] | | < 1 | | 0% | 1 study (1/-) | 7.7 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.43 [1.10, 5.37] | | < 1 | | 0% | 1 study (1/-) | 1.4 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 14.38 [0.81, 254.14] | | < 1 | | 0% | 1 study (1/-) | 3.6 % | NA | not evaluable | | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 1.27 [0.34, 4.75] | | < 1 | | 0% | 1 study (1/-) | 36.3 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.60 [0.14, 2.54] | | < 1 | | 0% | 1 study (1/-) | 75.3 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.03 [0.00, 0.20] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 1.35 [0.73, 2.49] | | < 1 | | 0% | 1 study (1/-) | 16.8 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 1.01 [0.02, 51.10] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 1.01 [0.14, 7.21] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 2.04 [0.61, 6.83] | | < 1 | | 0% | 1 study (1/-) | 12.4 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.04 [0.01, 0.30] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.14 [0.02, 1.16] | | < 1 | | 0% | 1 study (1/-) | 96.5 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 7.18 [0.88, 58.61] | | < 1 | | 0% | 1 study (1/-) | 3.4 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.63 [0.20, 1.93] | | < 1 | | 0% | 1 study (1/-) | 79.1 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.18 [0.08, 0.42] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 2.03 [0.37, 11.16] | | < 1 | | 0% | 1 study (1/-) | 20.8 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.85 [0.38, 1.92] | | < 1 | | 0% | 1 study (1/-) | 65.0 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.25 [0.05, 1.18] | | < 1 | | 0% | 1 study (1/-) | 95.9 % | NA | not evaluable | | non important | - |
| Chills AE (grade 3-4) | 2.03 [0.07, 60.53] | | < 1 | | 0% | 1 study (1/-) | 34.4 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 1.01 [0.02, 51.10] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 2.03 [0.07, 60.53] | | < 1 | | 0% | 1 study (1/-) | 34.4 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 2.30 [0.70, 7.54] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 2.55 [1.28, 5.06] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| Dizziness AE (grade 3-4) | 0.67 [0.11, 4.05] | | < 1 | | 0% | 1 study (1/-) | 66.7 % | NA | not evaluable | | non important | - |
| Dry skin AE (grade 3-4) | 1.01 [0.02, 51.10] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Dysgeusia AE (grade 3-4) | 1.01 [0.02, 51.10] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Dyspepsia AE (grade 3-4) | 1.01 [0.02, 51.10] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Dysphonia AE (grade 3-4) | 4.06 [0.18, 90.30] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 1.91 [0.75, 4.82] | | < 1 | | 0% | 1 study (1/-) | 8.7 % | NA | not evaluable | | non important | - |
| Epistaxis AE (grade 3-4) | 1.01 [0.02, 51.10] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.95 [0.46, 1.94] | | < 1 | | 0% | 1 study (1/-) | 56.0 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 1.01 [0.06, 16.22] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 1.67 [1.20, 2.32] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 1.01 [0.06, 16.22] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 1.95 [0.86, 4.42] | | < 1 | | 0% | 1 study (1/-) | 5.5 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 2.48 [1.21, 5.08] | | < 1 | | 0% | 1 study (1/-) | 0.7 % | NA | not evaluable | | non important | - |
| Mucosal inflammation AE (grade 3-4) | 1.01 [0.29, 3.52] | | < 1 | | 0% | 1 study (1/-) | 49.3 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.87 [0.29, 2.60] | | < 1 | | 0% | 1 study (1/-) | 60.2 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.03 [0.00, 0.20] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Oropharyngeal pain AE (grade 3-4) | 1.01 [0.02, 51.10] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) | 1.35 [0.73, 2.49] | | < 1 | | 0% | 1 study (1/-) | 16.8 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 2.03 [0.18, 22.45] | | < 1 | | 0% | 1 study (1/-) | 28.4 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 1.01 [0.02, 51.10] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 0.51 [0.02, 15.10] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 1.01 [0.14, 7.21] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
| Stomatitis AE (grade 3-4) | 2.04 [0.61, 6.83] | | < 1 | | 0% | 1 study (1/-) | 12.4 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.04 [0.00, 0.26] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.57 [0.17, 1.98] | | < 1 | | 0% | 1 study (1/-) | 81.0 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 3.09 [0.99, 9.66] | | < 1 | | 0% | 1 study (1/-) | 2.6 % | NA | not evaluable | | non important | - |
